Fast, controlled, and consistent: An exploration of current mRNA vaccine production technologies

When the first liposome-based drug, Doxil^®, was approved in the mid-1990s, decades of research spurred the need for more suitable lipid formulations with faster, better controlled, and more efficient manufacturing methods. Download this application note to find a review of the current technologies used for vaccine development.